Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
2.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M.

Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053.

3.

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.

Gong X, Litchfield LM, Webster Y, Chio LC, Wong SS, Stewart TR, Dowless M, Dempsey J, Zeng Y, Torres R, Boehnke K, Mur C, Marugán C, Baquero C, Yu C, Bray SM, Wulur IH, Bi C, Chu S, Qian HR, Iversen PW, Merzoug FF, Ye XS, Reinhard C, De Dios A, Du J, Caldwell CW, Lallena MJ, Beckmann RP, Buchanan SG.

Cancer Cell. 2017 Dec 11;32(6):761-776.e6. doi: 10.1016/j.ccell.2017.11.006.

4.

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.

Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.

Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23.

PMID:
29059158
5.

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.

Torres-Guzmán R, Calsina B, Hermoso A, Baquero C, Alvarez B, Amat J, McNulty AM, Gong X, Boehnke K, Du J, de Dios A, Beckmann RP, Buchanan S, Lallena MJ.

Oncotarget. 2017 May 10;8(41):69493-69507. doi: 10.18632/oncotarget.17778. eCollection 2017 Sep 19.

6.

Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair.

Lin AB, McNeely SC, Beckmann RP.

Clin Cancer Res. 2017 Jul 1;23(13):3232-3240. doi: 10.1158/1078-0432.CCR-16-0083. Epub 2017 Mar 22. Review.

7.

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.

Lowery CD, VanWye AB, Dowless M, Blosser W, Falcon BL, Stewart J, Stephens J, Beckmann RP, Bence Lin A, Stancato LF.

Clin Cancer Res. 2017 Aug 1;23(15):4354-4363. doi: 10.1158/1078-0432.CCR-16-2876. Epub 2017 Mar 7.

8.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

9.

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Tate SC, Burke TF, Hartman D, Kulanthaivel P, Beckmann RP, Cronier DM.

Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40.

10.

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.

Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB.

Pharmacol Ther. 2015 May;149:139-49. doi: 10.1016/j.pharmthera.2014.12.003. Epub 2014 Dec 27. Review.

PMID:
25550229
11.

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.

Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB.

Mol Cancer Ther. 2014 Oct;13(10):2253-63. doi: 10.1158/1535-7163.MCT-14-0257. Epub 2014 Aug 13.

12.

Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.

Tate SC, Cai S, Ajamie RT, Burke T, Beckmann RP, Chan EM, De Dios A, Wishart GN, Gelbert LM, Cronier DM.

Clin Cancer Res. 2014 Jul 15;20(14):3763-74. doi: 10.1158/1078-0432.CCR-13-2846. Epub 2014 May 21.

13.

The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.

Hamdouchi C, Keyser H, Collins E, Jaramillo C, De Diego JE, Spencer CD, Dempsey JA, Anderson BD, Leggett T, Stamm NB, Schultz RM, Watkins SA, Cocke K, Lemke S, Burke TF, Beckmann RP, Dixon JT, Gurganus TM, Rankl NB, Houck KA, Zhang F, Vieth M, Espinosa J, Timm DE, Campbell RM, Patel BK, Brooks HB.

Mol Cancer Ther. 2004 Jan;3(1):1-9.

14.

Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene.

Rao RN, Stamm NB, Otto K, Kovacevic S, Watkins SA, Rutherford P, Lemke S, Cocke K, Beckmann RP, Houck K, Johnson D, Skidmore BJ.

Oncogene. 1999 Nov 4;18(46):6343-56.

15.

Casein kinase 2 binds to and phosphorylates BRCA1.

O'Brien KA, Lemke SJ, Cocke KS, Rao RN, Beckmann RP.

Biochem Biophys Res Commun. 1999 Jul 14;260(3):658-64.

PMID:
10403822
16.

Identification of a BRCA1-associated kinase with potential biological relevance.

Burke TF, Cocke KS, Lemke SJ, Angleton E, Becker GW, Beckmann RP.

Oncogene. 1998 Feb 26;16(8):1031-40.

17.

Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1.

Thomas JE, Smith M, Rubinfeld B, Gutowski M, Beckmann RP, Polakis P.

J Biol Chem. 1996 Nov 8;271(45):28630-5.

18.
19.

Examining the function and regulation of hsp 70 in cells subjected to metabolic stress.

Beckmann RP, Lovett M, Welch WJ.

J Cell Biol. 1992 Jun;117(6):1137-50.

20.

Response of mammalian cells to metabolic stress; changes in cell physiology and structure/function of stress proteins.

Welch WJ, Kang HS, Beckmann RP, Mizzen LA.

Curr Top Microbiol Immunol. 1991;167:31-55. Review.

PMID:
2055098
21.

Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly.

Beckmann RP, Mizzen LE, Welch WJ.

Science. 1990 May 18;248(4957):850-4.

PMID:
2188360
22.

Use of an inducible hybrid viral gene as a model for evaluating drug effects on gene expression.

Beckmann RP, Beerman TA.

Mol Pharmacol. 1989 Apr;35(4):433-42.

PMID:
2468078
23.
24.

Supplemental Content

Loading ...
Support Center